The scientific goal of the Developmental Cancer Therapeutics Program is to discover and characterize unique agents and pathways that will impact the development of more effective cancer therapies and to translate these discoveries into clinical applications by using proof-of-principle, early phase clinical and correlative science studies.
Professor of Biochemistry & Molecular Biology | College of Medicine
Dr. Besim Ogretmen holds the Endowed Chair in Lipidomics & Drug Discovery, which is supported by the South Carolina SmartState® Center of Excellence and serves as Director of the Lipidomics Shared Resource. Dr. Ogretmen's research focuses on sphingolipid metabolism and lipid signaling with the long-term goal of developing mechanism-based therapeutic strategies against cancer.
Elizabeth S. Yeh, Ph.D., Assistant Professor of Cell & Molecular Pharmacology, examines how the deregulation of cellular signaling events results in the physiological changes that lead to human cancer, with a specific interest in breast cancer. Working with a team of senior scientists, Dr. Yeh assisted in the identification of a novel AMPK-related protein kinase called Hormonally Up-regulated Neu-associated Kinase (HUNK), whose function has been determined to be critical in the etiology and progression of human breast cancer. Dr. Yeh’s work demonstrated that HUNK promotes the survival of breast cancer cells, further suggesting that this molecule could be a therapeutic target. Dr. Yeh is now working to elucidate the intracellular mechanisms by which HUNK regulates survival signaling through the growth factor receptors, EGFR and HER2, two molecules that are commonly overrepresented in human breast cancer.
Learn more about Dr. Yeh